AbbVie Inc. v. Abby Tacher / Abbvie
Claim Number: FA2111001973938
Complainant is AbbVie Inc. ("Complainant"), represented by Molly Buck Richard of Richard Law Group, Inc., Texas, USA. Respondent is Abby Tacher / Abbvie ("Respondent"), Illinois, USA.
REGISTRAR AND DISPUTED DOMAIN NAME
The domain name at issue is <abbvieworldwide.com>, registered with Porkbun LLC.
The undersigned certifies that he has acted independently and impartially and to the best of his knowledge has no known conflict in serving as Panelist in this proceeding.
David E. Sorkin as Panelist.
Complainant submitted a Complaint to the Forum electronically on November 19, 2021; the Forum received payment on November 19, 2021.
On November 19, 2021, Porkbun LLC confirmed by email to the Forum that the <abbvieworldwide.com> domain name is registered with Porkbun LLC and that Respondent is the current registrant of the name. Porkbun LLC has verified that Respondent is bound by the Porkbun LLC registration agreement and has thereby agreed to resolve domain disputes brought by third parties in accordance with ICANN's Uniform Domain Name Dispute Resolution Policy (the "Policy").
On November 23, 2021, the Forum served the Complaint and all Annexes, including a Written Notice of the Complaint, setting a deadline of December 13, 2021 by which Respondent could file a Response to the Complaint, via email to all entities and persons listed on Respondent's registration as technical, administrative, and billing contacts, and to postmaster@abbvieworldwide.com. Also on November 23, 2021, the Written Notice of the Complaint, notifying Respondent of the email addresses served and the deadline for a Response, was transmitted to Respondent via post and fax, to all entities and persons listed on Respondent's registration as technical, administrative, and billing contacts.
Having received no response from Respondent, the Forum transmitted to the parties a Notification of Respondent Default.
On December 20, 2021, pursuant to Complainant's request to have the dispute decided by a single-member Panel, the Forum appointed David E. Sorkin as Panelist.
Having reviewed the communications records, the Administrative Panel (the "Panel") finds that the Forum has discharged its responsibility under Paragraph 2(a) of the Rules for Uniform Domain Name Dispute Resolution Policy (the "Rules") "to employ reasonably available means calculated to achieve actual notice to Respondent" through submission of Electronic and Written Notices, as defined in Rule 1 and Rule 2. Therefore, the Panel may issue its decision based on the documents submitted and in accordance with the ICANN Policy, ICANN Rules, the Forum's Supplemental Rules, and any rules and principles of law that the Panel deems applicable, without the benefit of any response from Respondent.
Complainant requests that the domain name be transferred from Respondent to Complainant.
A. Complainant
Complainant is a specialty-focused research-based biopharmaceutical company that employs approximately 48,000 persons in more than 70 countries, and that has annual revenues exceeding $45 billion. Complainant uses the ABBVIE mark in connection with its products and services, and owns registrations for ABBVIE in standard character form in the United States and many other jurisdictions, issued as early as 2012. Complainant asserts that the ABBVIE mark has become famous as a result of extensive use, promotion, and commercial success, and has been so found in at least one prior decision under the Policy. See AbbVie, Inc. v. AbbVie, FA 1773787 (Forum Mar. 28, 2018).
Respondent registered the disputed domain name <abbvieworldwide.com> via a privacy registration service in November 2021. The underlying registration data revealed when the privacy shield was removed in connection with this proceeding included Complainant's name and address, which according to Complainant were used without its permission.
The domain name currently redirects to Complainant's website, <abbvie.com>, and has been used in an email message sent to a vendor impersonating Complainant and seeking to purchase computers. Complainant states that Respondent is not commonly known by or authorized to use the ABBVIE mark and is not affiliated with Complainant in any way.
Complainant contends on the above grounds that the disputed domain name <abbvieworldwide.com> is confusingly similar to its ABBVIE mark; that Respondent lacks rights or legitimate interests in the disputed domain name; and that the disputed domain name was registered and is being used in bad faith.
B. Respondent
Respondent failed to submit a Response in this proceeding.
The Panel finds that the disputed domain name is confusingly similar to a mark in which Complainant has rights; that Respondent lacks rights or legitimate interests in respect of the disputed domain name; and that the disputed domain name was registered and is being used in bad faith.
Paragraph 15(a) of the Rules instructs this Panel to "decide a complaint on the basis of the statements and documents submitted in accordance with the Policy, these Rules and any rules and principles of law that it deems applicable."
Paragraph 4(a) of the Policy requires that Complainant must prove each of the following three elements to obtain an order that a domain name should be cancelled or transferred:
(1) the domain name registered by Respondent is identical or confusingly similar to a trademark or service mark in which Complainant has rights; and
(2) Respondent has no rights or legitimate interests in respect of the domain name; and
(3) the domain name has been registered and is being used in bad faith.
In view of Respondent's failure to submit a response, the Panel shall decide this administrative proceeding on the basis of Complainant's undisputed representations pursuant to paragraphs 5(f), 14(a), and 15(a) of the Rules and draw such inferences it considers appropriate pursuant to paragraph 14(b) of the Rules. The Panel is entitled to accept all reasonable allegations set forth in a complaint; however, the Panel may deny relief where a complaint contains mere conclusory or unsubstantiated arguments. See WIPO Overview of WIPO Panel Views on Selected UDRP Questions, § 4.3 (3d ed. 2017), available at http://www.wipo.int/amc/en/domains/search/overview3.0/; see also eGalaxy Multimedia Inc. v. ON HOLD By Owner Ready To Expire, FA 157287 (Forum June 26, 2003) (dismissing complaint where complainant failed to "produce clear evidence to support its subjective allegations").
The disputed domain name <abbvieworldwide.com> incorporates Complainant's registered ABBVIE trademark, adding the generic term "worldwide" and the ".com" top-level domain. These additions do not substantially diminish the similarity between the domain name and Complainant's mark. See, e.g., AbbVie, Inc. v. AbbVie, supra (finding <abbvie-jp.com> confusingly similar to ABBVIE); Abbvie, Inc. v. Richard Gonzalez, FA 1699131 (Forum Nov. 16, 2016) (finding <abbivie.com> confusingly similar to ABBVIE); Hoffmann-La Roche Inc. v. JoliMari, Joli Marikona, D2012-0315 (WIPO May 22, 2012) (finding <accutaneworldwide.com> confusingly similar to ACCUTANE); Warner Bros. Entertainment Inc. v. Jon Dives d/b/a warnerfilms, FA 1248657 (Forum Apr. 16, 2009) (finding <warnerworldwide.com> confusingly similar to WARNER BROS.). The Panel considers the disputed domain name to be confusingly similar to a mark in which Complainant has rights.
Under the Policy, the Complainant must first make a prima facie case that the Respondent lacks rights and legitimate interests in the disputed domain name, and then the burden shifts to the Respondent to come forward with concrete evidence of such rights or legitimate interests. See Hanna-Barbera Productions, Inc. v. Entertainment Commentaries, FA 741828 (Forum Aug. 18, 2006).
The disputed domain name incorporates Complainant's registered mark without authorization, and it is being used to impersonate Complainant for fraudulent purposes. Such use does not give rise to rights or legitimate interests under the Policy. See, e.g., Abbvie, Inc. v. Richard Gonzalez, supra (finding lack of rights or interests in similar circumstances).
Complainant has made a prima facie case that Respondent lacks rights and legitimate interests in the domain name, and Respondent has failed to come forward with any evidence of such rights or interests. Accordingly, the Panel finds that Complainant has sustained its burden of proving that Respondent lacks rights or legitimate interests in respect of the disputed domain name.
Finally, Complainant must show that the disputed domain name was registered and is being used in bad faith. Under paragraph 4(b)(iii) of the Policy, bad faith may be shown by evidence that Respondent registered the disputed domain name "primarily for the purpose of disrupting the business of a competitor." Under paragraph 4(b)(iv), bad faith may be shown by evidence that "by using the domain name, [Respondent] intentionally attempted to attract, for commercial gain, Internet users to [Respondent's] web site or other on-line location, by creating a likelihood of confusion with the complainant's mark as to the source, sponsorship, affiliation, or endorsement of [Respondent's] web site or location or of a product or service on [Respondent's] web site or location."
Respondent used a privacy registration service and at least partially fictitious underlying registration data to register a domain name corresponding to Complainant's well-known mark, and has used the domain name to impersonate Complainant in connection with a fraudulent phishing scheme. Such conduct is indicative of bad faith registration and use under the Policy. See, e.g., Abbvie, Inc. v. Richard Gonzalez, supra (finding bad faith in similar circumstances). The Panel so finds.
Having considered the three elements required under the ICANN Policy, the Panel concludes that relief shall be GRANTED.
Accordingly, it is Ordered that the <abbvieworldwide.com> domain name be TRANSFERRED from Respondent to Complainant.
David E. Sorkin, Panelist
Dated: December 23, 2021
Click Here to return to the main Domain Decisions Page.
Click Here to return to our Home Page